The 'atypicality' of antipsychotics: a concept re-examined and re-defined (Q37391972)

20 August 2017

1 reference

title

The 'atypicality' of antipsychotics: a concept re-examined and re-defined (English)

1 reference

20 August 2017

Gerhard Gründer

1

1 reference

20 August 2017

Hanns Hippius

series ordinal

2

1 reference

20 August 2017

Arvid Carlsson

series ordinal

3

1 reference

20 August 2017

language of work or name

1 reference

13 February 2009

1 reference

Nature Reviews Drug Discovery

20 August 2017

published in

1 reference

20 August 2017

volume

8

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

197-202

1 reference

Use of reserpine in disturbed psychotic patients.

20 August 2017

cites work

1 reference

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

21 January 2018

1 reference

No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457.

21 January 2018

1 reference

[Clinical experiences with a new piperazine derivative of phenothiazine in neuropsychiatry]

21 January 2018

1 reference

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

31 March 2020

1 reference

Atypical antipsychotics: are some more atypical than others?

31 March 2020

1 reference

An atypical compound by any other name is still a

31 March 2020

1 reference

Prolactin secretion is not a core dimension of "atypicality".

31 March 2020

1 reference

A meta-analysis of the efficacy of second-generation antipsychotics

31 March 2020

1 reference

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

31 March 2020

1 reference

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

31 March 2020

1 reference

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

31 March 2020

1 reference

Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence

31 March 2020

1 reference

Limbic selectivity of clozapine

31 March 2020

1 reference

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

31 March 2020

1 reference

Serotonin receptors: their key role in drugs to treat schizophrenia

31 March 2020

1 reference

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

31 March 2020

1 reference

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

31 March 2020

1 reference

The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia

31 March 2020

1 reference

Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine

31 March 2020

1 reference

Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels

31 March 2020

1 reference

Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study

31 March 2020

1 reference

Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study

31 March 2020

1 reference

Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia

31 March 2020

1 reference

High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia

31 March 2020

1 reference

Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.

31 March 2020

1 reference

Adaptive properties and heterogeneity of dopamine D(2) receptors - pharmacological implications

31 March 2020

1 reference

Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter.

31 March 2020

1 reference

Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization

31 March 2020

1 reference

Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study

31 March 2020

1 reference

Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride

31 March 2020

1 reference

Mechanism of new antipsychotic medications: occupancy is not just antagonism

31 March 2020

1 reference

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group

31 March 2020

1 reference

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

31 March 2020

1 reference

Antipsychotic drug doses and neuroleptic/dopamine receptors

31 March 2020

1 reference

Opinion: NK3 receptor antagonists: the next generation of antipsychotics?

31 March 2020

1 reference

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

31 March 2020

1 reference

Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders

31 March 2020

1 reference

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

31 March 2020

1 reference

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

31 March 2020

1 reference

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study

31 March 2020

1 reference

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia

31 March 2020

1 reference

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

31 March 2020

1 reference

Course and outcome of schizophrenia

31 March 2020

1 reference

Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria

31 March 2020

1 reference

Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative

31 March 2020

1 reference

Initial phase 2 trial of a nicotinic agonist in schizophrenia

31 March 2020

1 reference

Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia

31 March 2020

1 reference

A dopaminergic deficit hypothesis of schizophrenia: the path to discovery

31 March 2020

1 reference

12 December 2020

The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs

1 reference

12 December 2020

Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia

1 reference

12 December 2020

A historical perspective of clozapine.

1 reference

12 December 2020

Antipsychotic medications: metabolic and cardiovascular risk

1 reference

12 December 2020

Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)

1 reference

12 December 2020

[4 Cases of facio-bucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics]

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD2806

1 reference

20 August 2017

1 reference